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NADPH oxidases (NOX) are a major source of reactive oxygen species (ROS) production in the heart. ROS signaling regulates gene
expression, cell proliferation, apoptosis, and migration. However, the role of NOX2 in embryonic heart development remains
elusive. We hypothesized that deﬁciency of Nox2 disrupts endocardial to mesenchymal transition (EndMT) and results in
congenital septal and valvular defects. Our data show that 34% of Nox2-/- neonatal mice had various congenital heart defects
(CHDs) including atrial septal defects (ASD), ventricular septal defects (VSD), atrioventricular canal defects (AVCD), and
malformation of atrioventricular and aortic valves. Notably, Nox2-/- embryonic hearts show abnormal development of the
endocardial cushion as evidenced by decreased cell proliferation and an increased rate of apoptosis. Additionally, Nox2
deﬁciency disrupted EndMT of atrioventricular cushion explants ex vivo. Furthermore, treatment with N-acetylcysteine (NAC)
to reduce ROS levels in the wild-type endocardial cushion explants decreased the number of cells undergoing EndMT.
Importantly, deﬁciency of Nox2 was associated with reduced expression of Gata4, Tgfβ2, Bmp2, Bmp4, and Snail1, which are
critical to endocardial cushion and valvoseptal development. We conclude that NOX2 is critical to EndMT, endocardial cushion
cell proliferation, and normal embryonic heart development.

1. Introduction
Congenital heart defects (CHDs) are birth defects in infants
aﬀecting about 1% of live births [1, 2]. The most common
forms of CHDs are malformations of septal and valvular
structures, accounting for more than 40% of the cases [3, 4].
An intricate network of signaling molecules and transcription factors in the epicardium, myocardium, and endocardium regulates cardiac morphogenesis [5]. While advances
in genetic analysis have assisted in identifying genomic factors responsible for morphological abnormalities in patients
with CHDs [6], only less than 20% of CHDs are attributed
to chromosomal abnormalities or genetic mutations [7, 8].
Over 80% of CHDs have nongenetic or unknown causes
that may involve various environmental factors such as
maternal pregestational diabetes, obesity, and smoking [9],

indicating our limited knowledge on factors that regulate
cardiac morphogenesis.
Reactive oxygen species (ROS) are important signaling
molecules that modulate the intracellular redox state and
gene expression proﬁles to regulate cell proliferation, diﬀerentiation, apoptosis, and migration [10, 11]. An imbalance
in ROS production may have adverse eﬀects on fetal development [12, 13]. To this end, we and others have shown that
higher ROS levels in the embryonic heart alter gene expression proﬁle and result in a wide range of CHDs, suggesting
that overproduction of ROS disturbs normal heart development [14–16].
A critical process in embryonic heart development is the
epithelial to mesenchymal transition (EMT). The endocardial EMT (EndMT) is initiated at E9.5 in mice when endocardial cushion swellings are formed in the outﬂow tract (OFT)
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and atrioventricular (AV) canal regions [17]. With contributions from neural crest cells, endocardial cushions at OFT
and AV canal form the aorticopulmonary septum/semilunar
valves and AV valves/cardiac septum, respectively. EndMT
is regulated by transcription factors and signaling molecules
produced in the adjacent myocardium and endocardial
cushions [18].
NADPH oxidases (NOX) are a family of O2-- and H2O2producing enzymes expressed in both phagocytic and nonphagocytic cells [19]. The enzyme complex is composed of
NOX proteins (NOX1-5 and DUOX1-2), p22phox, p40phox,
p47phox, p67phox, and Rac GTPase. ROS production from
NOX enzymes by phagocytes plays an important role in killing invading pathogens. The heart also expresses NOX proteins. A major source of intercellular ROS production in
adult cardiomyocytes and embryonic cardiac stem cells is
NOX2 and NOX4 [20, 21]. Mutations of NOX genes result
in chronic granulomatous disease, a rare condition occurring
in 1 : 200,000-450,000 live births [22]. Notably, atrial septal
defects are also seen in patients with chronic granulomatous
disease [23], suggesting that mutations of NOX genes or a
lack of NOX-derived ROS production may cause CHDs.
However, the role of NOX enzymes in regulating cardiac
morphogenesis and their underlying molecular mechanisms
are not clear. In this study, we tested the hypothesis that deﬁciency of Nox2 disrupts EndMT and results in congenital
septal and valvular defects. Our data show that Nox2-/- mice
exhibit cardiac septal defects and valvular abnormalities. Furthermore, deﬁciency of Nox2 impairs EndMT and AV endocardial cushion development. Our study reveals a critical role
of NOX2-derived ROS signaling in EndMT and normal heart
development.

2. Materials and Methods
2.1. Animals. Nox2-/- (B6.129S-Cybbtm1Din/J, Stock No.
002365) and C57BL/6 mice were purchased from Jackson
Laboratory (Bar Harbor, Maine). Nox2-/- mice were backcrossed to C57BL/6 background for more than ten generations; therefore, C57BL/6 mice were used as a control in all
experiments. PCR analysis was performed to validate the
Nox2 gene knockout model using the following primers: 5 ′
AAGAGAAACTCCTCTGCTGTGAA 3 ′ and 5 ′ GTTCTA
ATTCCATCAGAAGCTTATCG 3 ′ , provided by Jackson
Laboratory. A breeding program was implemented to harvest fetal and postnatal mice. Animals in this study were
handled in accordance with the Guide for the Care and Use
of Laboratory Animals, published by the U.S. National Institutes of Health (8th edition, 2011). All procedures involving
mouse handling and manipulation were in accordance with
the guidelines of the Canadian Council of Animal Care
and approved by the Animal Care Committee at Western
University, Canada.
2.2. Heart Morphology and Immunohistochemistry. Heart
morphology in postnatal day 0 (P0) mice was analyzed on
serial heart sections under a microscope. Brieﬂy, the mouse
thorax was ﬁxed in 4% paraformaldehyde overnight, dehydrated in ethanol, embedded in paraﬃn medium, and sec-

Oxidative Medicine and Cellular Longevity
tioned transversely to 5 μm serial sections. For assessment
of AV valve thickness and length, serial sections of each heart
were evaluated at P0. The longest and thickest region of each
valve leaﬂet was quantiﬁed in at least 3 serial sections. E10.5
embryos were harvested to assess cell density in the AV cushion. For immunohistochemical staining, antigen retrieval
was performed in citric acid buﬀer (0.01 M, pH 6.0) for 12
minutes at 94°C using a microwave oven (BP-111, Microwave Research & Applications, Carol Stream, Illinois). Tissue
sections were incubated with the following primary antibodies overnight: Ki67 (1 : 500, Abcam), activated caspase-3
(1 : 800, Cell Signaling), Snail1 antibody (1 : 300, Abcam)
and NOX2 (1 : 500, BD Transduction Laboratories) followed
by one of the following secondary antibodies (Vector Laboratories) for an hour: biotinylated goat anti-rabbit IgG (1 : 500)
or biotinylated goat anti-mouse IgG (1 : 500). Signals were
ampliﬁed by incubation with the ABC reagent (Vector
Laboratories) and visualized using 3,3 ′ -diaminobenzidine
tetrahydrochloride (Sigma-Aldrich). Heart sections were
counterstained with modiﬁed Mayer’s hematoxylin (Thermo
Scientiﬁc), and images were captured using a light microscope
(Observer D1, Zeiss, Germany).
2.3. Analysis of ROS Levels. Frozen sections (10 μm) of E10.5
hearts were employed to assess superoxide levels using
dihydroethidium (DHE) (Invitrogen Life Technologies,
Burlington, Canada) as we previously described [15]. Brieﬂy,
heart sections were incubated with 2 μM DHE for 30 minutes
in a humidiﬁed and light-protected chamber in room air at
37°C. DHE ﬂuorescence signals were detected using a ﬂuorescence microscope (Observer D1, Zeiss, Germany). Myocardial images (5 from each heart section) were captured
using ﬁxed exposure time for both groups. The intensity of
ﬂuorescence signals per myocardial area was quantiﬁed using
AxioVision software.
2.4. Real-Time RT-PCR Analysis. Total RNA was extracted
from E10.5 fetal hearts using a RNeasy Mini kit (Qiagen,
Burlington, ON) as per manufacturer’s instructions. cDNA
was synthesized using M-MLV reverse transcriptase. At least
two hearts were pooled for each qPCR analysis. Real-time
PCR was conducted using EvaGreen qPCR MasterMix
(Applied Biological Materials, Vancouver, BC). Speciﬁc
primers were designed for Nkx2.5, Gata4, Gata5, Tbx5,
Bmp2, Bmp4, Tgf-β2, Snail1, and Mef2c (Table 1). Samples
were ampliﬁed for 35 cycles using Eppendorf Realplex
(Eppendorf, Hamburg). The mRNA levels in relation to 28S
ribosomal RNA were determined using a comparative CT
method [15].
2.5. Ex Vivo Endocardial Cushion Explant Culture. Endocardial to mesenchymal transition (EndMT) was assessed
ex vivo. AV cushions of similar size E10.5 embryos from
Nox2-/- and control dams were harvested and cultured on
collagen gel. Collagen (1 mg/ml, type I collagen of rat’s tail,
BD Biosciences) was prepared in M199 culture media
(M5017, Sigma). Casted collagen was hydrated by OPTIMEM media plus 1% of fetal bovine serum (FBS) and
insulin-transferrin-selenium (ITS) for 30 minutes at 37°C.
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Table 1: Sequences of primers used for real-time PCR analysis.
Gene

Accession No.

Product size (bp)

Bmp2

NM_007553.3

151

Bmp4

NM_007554.2

250

Gata4

NM_008092.3

134

Gata5

NM_008093.2

167

Mef2c

NM_001170537.1

405

Nkx2.5

NM_008700.2

162

Snail1

NM_011427.2

114

Tbx5

NM_011537.3

103

Tgf-β2

NM_009367.3

230

Notch1

NM_008714.3

142

28S

NR_003279.1

178

Primer sequence (5 ′ → 3 ′ )
F: CAAACACAAACAGCGGAAGC
R: CAGCAAGGGCAAAAGGACAC
F: GTTATGAAGCCCCCAGCAGA
R: CCCAATCTCCACTCCCTTGA
F: GCCTGCGATGTCTGAGTGAC
R: CACTATGGGCACAGCAGCTC
F: ACCCCACAACCTACCCAGCA
R: GCCCTCACCAGGGAACTCCT
F: CACCGAGTACAACGAGCCGCA
R: CTGGTGCCTGCACCGGATGTC
F: GACAGCGGCAGGACCAGACT
R: CGTTGTAGCCATAGGCATTG
F: CACACGCTGCCTTGTGTCT
R: GGTCAGCAAAAGCACGGTT
F: AGGAGCACAGTGAGGCACAA
R: GGGCCAGAGACACCATTCTC
F: CTGTGCAGGAGTGGCTTCAC
R: GCAGGAGATGTGGGGTCTTC
F: CAGCTTGCACAACCAGACAGA
R: TAACGGAGTACGGCCCATGT
F: GGGCCACTTTTGGTAAGCAG
R: TTGATTCGGCAGGTGAGTTG

F and R indicate forward and reverse primers, respectively.

The AV cushion regions together with the overlying myocardium were explanted, cut open, and seeded with the cushion
side facing the collagen gel at 37°C overnight. The following
day, the AV cushions adhered to the collagen gel and M199
media with 10% of FBS were added to the explants. To inhibit
ROS production, heart explant cultures were treated with
5 mM N-acetylcysteine (NAC). The number of spindleshaped cell outgrowth from the explanted cushions was
quantiﬁed 3 days post culturing [24]. Phase contrast images
were captured using an Observer D1 microscope (Zeiss,
Germany).
2.6. Statistical Analysis. Data are presented as means ± SEM.
Statistical analysis was performed using Student’s t-test or
two-way analysis of variance (ANOVA) followed by a
Bonferroni post hoc test. The survival rate and incidence
of congenital malformations were analyzed by a Chisquared test. A P value of less than 0.05 was considered
statistically signiﬁcant.

3. Results
3.1. Reduced Viability, Litter Size, and Body Weight in Nox2-/Neonates. Litter size in Nox2-/- mice was smaller (P < 0:05,
Figure 1(a)), and their body weight at birth was signiﬁcantly
lower compared to wild-type (WT) controls (P < 0:05,
Figure 1(b)). A signiﬁcant smaller body size or growth retardation was observed in 6 out of 25 (24%) Nox2-/- embryos
collected at E10.5-12.5 while this was not seen in any of the
29 WT embryos (n = 4 litters per group, Figure 1(c)). It is

possible that the embryos with drastic growth retardation
die during gestation, explaining the 25% reduction in litter
size at birth. Animal survival after birth was monitered for
21 days with Nox2-/- mice showing a signiﬁcant lower
survival compared to WT mice (72% vs. 92%, P < 0:001,
Figure 1(d)).
3.2. Septal and Valve Defects in Nox2-/- Mice. Histological
analysis of Nox2-/- hearts at P0 shows that 34% of Nox2-/mice were born with various CHDs including atrial septal
defects (ASD, 18%), ventricular septal defects (VSD, 18%),
and severe cases of septal malformation in the form of atrioventricular canal defects (AVCD, 3.3%), which are septation
defects (Table 2, Figure 2(a)). Furthermore, 6.6% of Nox2-/neonates showed bicuspid aortic valves (BAV, Table 2,
Figure 2(a)). Notably, all cases of BAV were associated with
septal abnormalities. Most Nox2-/- mice had a single ASD
or VSD. However, 2 out of 61 Nox2-/- mice (3.3%) had both
ASD and VSD. Nox2-/- hearts with septal defects also had
malformations of atrioventricular valves (Figure 2(b)). Speciﬁcally, the mitral and tricuspid valves were shortened in
length (Figure 2(e)) and the distal tip of mitral (P < 0:05)
but not tricuspid valves was enlarged in Nox2-/- mice
(Figures 2(f) and 2(g)). In addition, there was a larger area
in the AV valves stained by toluidine blue indicating a higher
level of extracellular proteoglycan in Nox2-/- mice (Figures 2(c)
and 2(h)). Similarly, picrosirius red staining for extracellular
collagen ﬁbers indicated higher levels of collagen deposition
in both mitral and tricuspid valves (P < 0:001 and P < 0:05,
Figures 2(d) and 2(i)).
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Figure 1: Litter size, body weight, and survival of Nox2 mice. (a) Litter size at birth, calculated based on average number of animals per
pregnancy. N = 10‐13 litters per group. (b) Body weight of neonates at birth, N = 28 samples per group. (c) Representative images of body
size of WT and Nox2-/- mice at E10.5. Scale bar is 1 mm. (d) Survival rate in Nox2-/- mice during the ﬁrst three weeks of life compared to
their age-matched controls. N = 129 in the wild-type (WT) group and N = 112 in the Nox2-/- group. ∗ P < 0:05, ∗∗ P < 0:001 by unpaired
Student’s t-test in (a, b) and the Chi-squared test in (d).
-/-

Table 2: Incidence of congenital heart defects in Nox2-/- mice at P0.
Wild type
(N = 35 of
5 litters)

Nox2-/(N = 61 of
12 litters)

N

%

N

Normal

35

100

40

65.6∗∗

Abnormal

0

0

21

34.4∗∗

ASD

0

0

11

18∗

VSD

0

0

11

18∗

AVCD
BAV

0
0

0
0

2
4

3.3
6.6

%

ASD: atrial septal defect; VSD: ventricular septal defect; AVCD:
atrioventricular canal defect. ∗ P < 0:05, ∗∗ P < 0:01 vs. wild-type by the Chisquared test.

3.3. NOX2 Expression Pattern and Endocardial Cushion
Formation at E10.5. To examine the expression pattern of
NOX2, immunohistochemical analysis was performed.
NOX2 immunostaining was observed in the atrial and ventricular myocardium of WT at E10.5 (Figure 3(a)). NOX2
expression was more robust on the left ventricular myocardium compared to the right (Figures 3(c) and 3(d) ). Importantly, NOX2 was also expressed in the myocardium
overlying the endocardial cushions at the AV canal, suggesting
a possible role in regulating endocardial cushion development
(Figure 3(e)). Notably, the epicardium, endocardium, and cells
within the endocardial cushion do not express NOX2 in the
WT hearts at E10.5. As expected, Nox2-/- hearts showed negative NOX2 immunostaining in the myocardium and lower
cellular density in the endocardial cushion by hematoxylin
staining compared to WT hearts at E10.5 (Figures 3(b) and
3(f)). Furthermore, ROS levels as assessed by dihydroethidium ﬂuorescence intensity were signiﬁcantly lower in the
Nox2-/- myocardium (P < 0:05, Figures 4(a) and 4(b)).
3.4. EndMT Is Impaired in Nox2-/- Hearts. To investigate the
role of Nox2 in endocardial cushion formation, we evaluated
AV EndMT of endocardial cells in vivo and in vitro. To this
end, expression levels of Snail1, a marker of EMT [25], were

analyzed. Our data show that Snail1 mRNA levels at E10.5 as
well as the number of Snail1-positive cells in the AV endocardial cushion at E12.5 were lower in Nox2-/- compared to WT
embryos (P < 0:05, Figures 5(a), 5(c), and 5(d) ). To examine
EndMT, the AV endocardial cushion of E10.5 fetal hearts
was cultured on collagen gel and allowed for cell outgrowth
for three days (Figure 5(b)). The number of spindle-shaped
cells, which had undergone EndMT, was quantiﬁed. Nox2-/endocardial cushions had a signiﬁcantly lower number of
spindle-shaped cells compared to WT cushions (P < 0:05,
Figures 5(b) and 5(e)). To reduce ROS levels, WT and
Nox2-/- AV cushion explants were treated with a ROS quenching agent, N-acetylcysteine (NAC). Notably, treatment with
NAC further diminished EndMT of AV cushions in both
WT and Nox2-/- samples (P < 0:001, Figures 5(b) and 5(e)).
3.5. Nox2 Deﬁciency Reduces Expression of Genes Crucial to
Cushion Development. To further investigate the role of
Nox2 in regulating EndMT, we examined the expression of
transcription factors and growth factors critical to EndMT
and heart development in 10.5 hearts. Our data show that
mRNA levels of Gata4, a transcription factor important to
septal development, were diminished in Nox2-/- mice
(P < 0:05, Figure 6(a)). Also, the expression levels of members of the TGF-β superfamily, including Tgf-β2, Bmp2,
and Bmp4, which are important regulators of endocardial
cushion formation [26], were signiﬁcantly lower in Nox2-/fetal hearts at E10.5 (P < 0:05, Figures 6(b)–6(d)). We also
analyzed mRNA levels of other regulators of cardiac septum
formation such as Nkx2.5, Gata5, Mef2c, Tbx5, TGFβ1, and
Notch1; however, their expression levels were not signiﬁcantly
altered in Nox2-/- embryonic hearts (Figures 6(e)–6(j)).
3.6. Nox2 Deﬁciency Increases Apoptosis and Reduces Cell
Proliferation in Endocardial Cushion. ROS regulates cell proliferation and apoptosis in a variety of cell types. Using
immunostaining of cleaved caspase-3 protein, we analyzed
cell apoptosis in the AV endocardial cushion at E10.5. Nox2
deﬁciency resulted in a 2-fold higher apoptosis in the AV
endocardial cushion (P < 0:05, Figures 7(a) and 7(b)). We
also assessed cell proliferation using Ki67 immunostaining
(Figure 7(c)). Data was collected from 3-6 heart sections with
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Figure 2: Congenital heart defects in Nox2-/- mice at P0. (a) Representative histological images of normal and abnormal hearts. Nox2-/- mice
exhibited ASD, a complete AVCD (arrows point to interrupted septum primum and VSD), and membranous and muscular (arrows) types of
VSD. (b) Representative histological images of tricuspid and mitral valves. (c) Toluidine blue staining of extracellular glycosaminoglycans
(light purple) in AV valves. (d) Picrosirius red staining of collagen ﬁbers. (e–g) Quantiﬁcation of mitral and tricuspid valve length and AV
valve thickness. (h) Quantiﬁcation of the total glycosaminoglycan- (GAG-) positive area in AV valves. (i) Quantiﬁcation of collagen
deposition in mitral and tricuspid valves. ∗ P < 0:05 and ∗∗∗ P < 0:001 vs. WT by Student’s t-test. N = 9‐12 per group. Scale bar in (a) is
200 μm and 100 μm in (b–d).
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myocardium of WT hearts. (e) Arrows indicate NOX2 expression in the myocardium overlying AV endocardial cushion in WT but not
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Figure 4: Analysis of superoxide levels in fetal hearts at E10.5 using dihydroethidium (DHE) as a probe. (a) Representative images of ROS
levels in the left ventricular myocardium. (b) Quantiﬁcation of DHE ﬂuorescence intensity. Scale bar is 20 μm. N = 3 hearts per group.
∗
P < 0:01 vs. WT by unpaired Student’s t-test.

bulging AV endocardial cushion per heart, a total of 5 hearts
per group. Our data show a 50% lower cell proliferation rate
in the AV endocardial cushion of Nox2-/- compared to WT
embryos (P < 0:001, Figures 7(c) and 7(d)). Furthermore, cellular density in the AV endocardial cushion of Nox2-/- hearts
was signiﬁcantly lower than that of WT controls (P < 0:05,
Figure 7(e)).

4. Discussion
EMT is a process by which epithelial cells undergo their
phenotypic transformation to become mesenchymal cells
[27, 28]. These multipotent mesenchymal cells are able to differentiate into a variety of cell types. Cells that undergo EMT
lose their cell-cell junctions and epithelial cell polarity
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Figure 5: Analysis of endocardial EMT in vivo and in vitro. (a) Representative images of Snail1 expression in the endocardial cushion (EC) at
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Figure 6: Analysis of mRNA levels in fetal hearts at E10.5. (a–d) The mRNA levels of Gata4, Tgfβ2, Bmp2, and Bmp4 in Nox2-/- fetal hearts
were signiﬁcantly lower than those of WT levels. (e–j) Expression levels of Nkx2.5, Gata5, Mef2c, Tbx5, Tgfβ1, and Notch1 were not altered
in Nox2-/- fetal hearts. N = 7‐9 hearts per group. At least two hearts were pooled for each qPCR analysis. ∗ P < 0:01 vs. WT by unpaired
Student’s t-test.

followed by cytoskeletal reorganization and activation of the
mesenchymal gene program. EMT is critical to many developmental, physiological, and pathological processes including organogenesis, wound healing, tissue ﬁbrosis, and
cancer metastasis. In heart embryogenesis, EndMT and epicardial EMT are essential for the development of cardiac valves/septum and coronary arteries, respectively [17, 29]. ROS
derived from NADPH oxidases have been shown to promote
EMT in numerous cell types. For example, ROS-mediated
TGFβ signaling in the regulation of EMT has been shown
in keratinocytes [30] and alveolar cells [31]. NOX2-derived
ROS signaling has been shown to mediate the EMT process
of human breast cancer cells [32]. NOX4 plays a role in
TGFβ-driven EMT in lens epithelial cells to form myoﬁbroblasts, resulting in cataract [33]. ROS signaling is critical to
TGFβ1-induced renal tubular EMT in renal inﬂammation/ﬁbrosis in angiotensin II-induced hypertension [34]. Additionally, ROS derived from NOX1 and NOX4 have been
shown to drive cardiac diﬀerentiation and cardiomyocyte

proliferation through regulating cardiac transcription factor
expression [20, 35, 36]. However, the role of NOX2 in embryonic heart morphogenesis remains unknown. The present
study demonstrated that one-third of Nox2-/- neonates had
CHDs including septal defects, AVCD, and AV valve malformation. Importantly, Nox2 deﬁciency resulted in signiﬁcantly lower EndMT and cell proliferation in endocardial
cushions. Pharmacological inhibition of ROS production
impaired EndMT in endocardial cushion explants. Furthermore, Nox2 deﬁciency reduced the expression of genes critical to EndMT and AV endocardial cushion development,
including Gata4, Tgfβ2, Bmp2, Bmp4, and Snail1. Our study
shows for the ﬁrst time that NOX2-mediated ROS signaling
is critical to AV cushion EndMT, cell proliferation/survival,
and normal heart morphogenesis (Figure 8).
A network of signaling molecules and transcription factors in myocardial and endocardial cells regulates EndMT.
TGFβ2 is expressed in the endocardium and myocardium
at the AV and OFT regions during cushion formation [37].

Oxidative Medicine and Cellular Longevity

9
Nox2-/-

Cleaved caspase-3+ cells (%)

Cleaved caspase-3

WT

1.5
⁎
1.0
0.5
0.0

(a)

WT

Nox2-/-

(b)

Nox2-/-

WT

Ki67+ cells (%)

100
80
60
⁎

40
20
0

WT

Nox2-/-

Ki67

(d)

Cell density/0.1 mm2

50
40

20
10
0

(c)

⁎

30

WT

Nox2-/-

(e)

Figure 7: Apoptosis and cell proliferation in endocardial cushions. (a) Representative images of histological sections immunostained for
cleaved caspase-3 protein at E10.5. Arrows point to positive cells (brown). (b) Quantiﬁcation of cleaved caspase-3-positive cells at E10.5.
(c) Representative images of Ki67 immunostaining in E12.5 hearts. Quantiﬁcation of Ki67-positive cells (d) and cell density (e) in
endocardial cushions at E12.5. Lower panels (scale bars =10 μm) are enlargement of the boxed areas of the upper panels (scale
bars =100 μm) in (a, b). n = 5‐7 hearts per group. ∗ P < 0:05 vs. WT by unpaired Student’s t-test.

BMP2 and BMP4 are released from the myocardium promoting EndMT in the AV canal [25]. Through activation of
BMP receptors on endocardial cells, they increase the endocardial expression of Gata4, Tgf-β2, and Snail1, which are
essential for EndMT [38]. In the present study, we demonstrated that NOX2 is also expressed in the myocardium overlying the endocardial cushion. The proximity of NOX2
expression allows NOX2-derived ROS to regulate BMP2/4
expression in the myocardium and subsequent TGFβ signaling in the endocardial cushion. Interestingly, ROS also stimulate Snail1 transcription and EMT in mammary epithelial
cells [39, 40]. Additionally, a reduction in ROS signaling from
a knockdown of glucose-6-phosphate dehydrogenase, the
enzyme that generates NADPH, impairs EMT and embryonic
development in zebraﬁsh [41]. The reduced AV cushion

EndMT along with decreased expression of Bmp2/4, Tgf-β2,
and Snail1 in Nox2-/- hearts in our study strongly suggest that
NOX2-derived ROS promotes BMP/TGFβ signaling and AV
cushion EndMT in embryonic heart development.
Cell proliferation and apoptosis are key cellular events
that regulate heart development during embryogenesis. It is
generally believed that excessive levels of ROS favor cell
apoptosis [42]. Consistent with this notion, we recently
showed that increased ROS production during pregestational
diabetes reduces cell proliferation and increases apoptosis in
the endocardial cushion [15]. N-Acetylcysteine treatment
restored cell proliferation but not apoptosis. Surprisingly,
lowering ROS levels in control mice by N-acetylcysteine
treatment increases cell apoptosis [15]. In the present study,
deﬁciency in Nox2 results in lower ROS in E10.5 hearts,
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Figure 8: Schematic summary of NOX2-mediated ROS signaling in directing EndMT and valvoseptal development. ROS production from
NOX2 positively regulates the expression of factors that promote EndMT and formation of normal valvoseptal structures.

higher cell apoptosis, and lower cell proliferation in the endocardial cushion. These ﬁndings suggest that physiological
levels of ROS are critical to cell survival and proliferation during embryonic heart development. ROS signaling has been
shown to induce developmental gene expression [42]. Thus,
lower expression of Gata4, Bmp2/4, and Tgf-β2 observed in
the present study may lead to higher apoptosis and lower cellular density in the endocardial cushion of Nox2-/- hearts. The
reduced cell proliferation and AV cushion EndMT in combination with higher apoptosis may contribute to CHDs in
Nox2-/- mice.
A limitation of this study is the use of a whole body Nox2
knockout mouse. The possible impact of loss of NOX2 expression in tissues outside the cardiovascular system cannot be
ruled out. For example, cardiac neural crest cells delaminated
from the dorsal neural tube are critical to outﬂow tract development. It is likely that lack of NOX2 expression in the cardiac
neural crest cells may impede their migration to the outﬂow
tract leading to the bicuspid aortic valve, a hypothesis that
needs to be further tested in future studies. Additionally, the
Nox2-/- mice show a signiﬁcant but relatively low penetrance
of CHDs (34%). It is not clear if other NOX isoforms or
ROS-producing enzymes are compensated for the global loss
of Nox2 in this model. An extension to this study could be
using tissue-speciﬁc and inducible animal models or generating animals with deﬁciency in both Nox2 and 4 genes.
In summary, deﬁciency in Nox2 results in congenital
defects of the cardiac septum and valves. We further demonstrated that a lack of NOX2-derived ROS production
decreases gene expression in the developing heart and disrupts AV cushion EndMT with lower cell proliferation and

higher apoptosis in the endocardial cushion. Taken together,
our study shows that endogenous ROS signaling from NOX2
is critical to normal heart development in mice. Importantly,
our study provides a mechanistic insight into the pathogenesis of congenital heart defects in patients with chronic granulomatous disease [23].
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